L Sandberg1, M Biström1, J Salzer1, M Vågberg1, A Svenningsson1, P Sundström2. 1. Department of Pharmacology and Clinical Neuroscience, Section of Neurology, Umeå University, Umeå, Sweden. 2. Department of Pharmacology and Clinical Neuroscience, Section of Neurology, Umeå University, Umeå, Sweden peter.sundstrom@neuro.umu.se.
Abstract
BACKGROUND: Previous studies in patients with multiple sclerosis (MS) have shown an association between high serum 25-hydroxyvitamin D (25[OH]D) levels and decreased inflammatory activity. OBJECTIVE: The purpose of this study was to examine the association between 25(OH)D levels and axonal injury in MS. Cerebrospinal fluid neurofilament light (CSF-NFL) was used as a marker for axonal injury. METHODS: Patients were identified through clinical practice at the Department of Neurology in Umeå University Hospital, Sweden. Blood draw, magnetic resonance imaging, scoring of disability and lumbar puncture were performed at inclusion in 153 patients, and also at median 12 months follow-up in 87 patients. For analyses of serum 25(OH)D levels and CSF-NFL, enzyme-linked immunosorbent assays were used. RESULTS: There was an inverse association between serum 25(OH)D and CSF-NFL levels in categorical (dichotomized at 75 or 100 nmol/l) analyses. A dose-response effect for 25(OH)D levels on CSF-NFL levels (p for trend=0.034) was also present. Serum 25(OH)D levels above 100 nmol/l were associated with lower CSF-NFL levels independently of ongoing MS treatment. CONCLUSION: High 25(OH)D levels are associated with decreased axonal injury in MS.
BACKGROUND: Previous studies in patients with multiple sclerosis (MS) have shown an association between high serum 25-hydroxyvitamin D (25[OH]D) levels and decreased inflammatory activity. OBJECTIVE: The purpose of this study was to examine the association between 25(OH)D levels and axonal injury in MS. Cerebrospinal fluid neurofilament light (CSF-NFL) was used as a marker for axonal injury. METHODS:Patients were identified through clinical practice at the Department of Neurology in Umeå University Hospital, Sweden. Blood draw, magnetic resonance imaging, scoring of disability and lumbar puncture were performed at inclusion in 153 patients, and also at median 12 months follow-up in 87 patients. For analyses of serum 25(OH)D levels and CSF-NFL, enzyme-linked immunosorbent assays were used. RESULTS: There was an inverse association between serum 25(OH)D and CSF-NFL levels in categorical (dichotomized at 75 or 100 nmol/l) analyses. A dose-response effect for 25(OH)D levels on CSF-NFL levels (p for trend=0.034) was also present. Serum 25(OH)D levels above 100 nmol/l were associated with lower CSF-NFL levels independently of ongoing MS treatment. CONCLUSION: High 25(OH)D levels are associated with decreased axonal injury in MS.
Authors: Marianna Vitkova; Ibrahima Diouf; Charles Malpas; Dana Horakova; Eva Kubala Havrdova; Francesco Patti; Serkan Ozakbas; Guillermo Izquierdo; Sara Eichau; Vahid Shaygannejad; Marco Onofrj; Alessandra Lugaresi; Raed Alroughani; Alexandre Prat; Catherine Larochelle; Marc Girard; Pierre Duquette; Murat Terzi; Cavit Boz; Francois Grand'Maison; Patrizia Sola; Diana Ferraro; Pierre Grammond; Helmut Butzkueven; Katherine Buzzard; Olga Skibina; Bassem I Yamout; Rana Karabudak; Oliver Gerlach; Jeannette Lechner-Scott; Davide Maimone; Roberto Bergamaschi; Vincent Van Pesch; Gerardo Iuliano; Elisabetta Cartechini; Maria José Sà; Radek Ampapa; Michael Barnett; Stella E Hughes; Cristina M Ramo-Tello; Suzanne Hodgkinson; Daniele L A Spitaleri; Thor Petersen; Ernest Gerard Butler; Mark Slee; Chris McGuigan; Pamela Ann McCombe; Franco Granella; Edgardo Cristiano; Julie Prevost; Bruce V Taylor; Josã Luis Sãnchez-Menoyo; Guy Laureys; Liesbeth Van Hijfte; Steve Vucic; Richard A Macdonell; Orla Gray; Javier Olascoaga; Norma Deri; Yara Dadalti Fragoso; Cameron Shaw; Tomas Kalincik Journal: Neurology Date: 2022-04-11 Impact factor: 11.800
Authors: Vanitha A Jagannath; Graziella Filippini; Carlo Di Pietrantonj; G V Asokan; Edward W Robak; Liz Whamond; Sarah A Robinson Journal: Cochrane Database Syst Rev Date: 2018-09-24
Authors: Lenka Novakova; Henrik Zetterberg; Peter Sundström; Markus Axelsson; Mohsen Khademi; Martin Gunnarsson; Clas Malmeström; Anders Svenningsson; Tomas Olsson; Fredrik Piehl; Kaj Blennow; Jan Lycke Journal: Neurology Date: 2017-10-27 Impact factor: 9.910